GlassScriptPhysician profile
Narothama Reddy Aeddula
NPI 1255581641
$125,249.35
in general payments reported to CMS, 2019-2025
14 companies · $50K in 2025
The $50K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $150 · 2023: $21K · 2024: $54K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $40K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Travel and Lodging: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Consulting Fee: $6,000 · Food and Beverage: $5,616 · Education: $26.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $40,050.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,500.70 |
| Travel and Lodging | $24,319.92 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,300.00 |
| Consulting Fee | $6,000.00 |
| Food and Beverage | $5,615.79 |
| Education | $26.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $59,326.68 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $53,397.53 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $11,277.95 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $364.62 | 2022-2025 | Tavneos, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $181.10 | 2023-2025 | |
| Abbvie INC. | $144.81 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $128.03 | 2023 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $122.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.45 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $72.85 | 2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $63.77 | 2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $29.20 | 2025 | |
| Apellis Pharmaceuticals, INC. | $20.34 | 2025 | Empaveli |
| Vifor Pharma, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narothama Reddy Aeddula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.